From: Research progress on non-protein-targeted drugs for cancer therapy
Target | Drug name | Cancer | ClinicalTrials. gov Identifier | Current status |
---|---|---|---|---|
RRM2 | CALAA-01 | Solid tumor | NCT00689065 | Phase I terminated |
PKN3 | Atu027 | Advanced solid cancer | NCT00938574 | Phase I completed |
Atu027 | Advanced or metastatic pancreatic cancer | NCT01808638 | Phase Ib/IIa completed | |
KRAS | siG12D LODER | Pancreatic cancer | NCT01188785 | Phase I completed |
siG12D LODER | Pancreatic Cancer | NCT01676259 | Phase II recruiting | |
NBF-006 | NSCLC, pancreatic cancer, CRC | NCT03819387 | Phase I recruiting | |
KrasG12D mutation | KRAS G12D siRNA | Pancreatic cancer | NCT03608631 | Phase I recruiting |
PLK1 | TKM-080301 | CRC | NCT01437007 | Phase I completed |
TKM-080301 | HCC | NCT02191878 | Phase I/II completed | |
EphA2 | siRNA-EphA2 DOPC | Advanced or recurrent solid tumors | NCT01591356 | Phase I recruiting |
MYC | DCR-MYC | Solid tumors, multiple myeloma, lymphoma | NCT02110563 | Phase I terminated |
DCR-MYC | HCC | NCT02314052 | Phase Ib/II terminated | |
Bcl2L12 | NU-0129 | GBM | NCT03020017 | Early Phase I completed |
TLR9/STAT3 | CpG-STAT3 siRNA CAS3/SS3 | B-cell non-hodgkin lymphoma | NCT04995536 | Phase I recruiting |
TGF-β1/COX-2 | STP705 | Squamous cell carcinoma | NCT04844983 | Phase II recruiting |